Wegovy is generally a better fit than Ozempic for weight loss because it is FDA-approved for chronic weight management. Ozempic is also a GLP-1 medication, so "GLP-1" and "Ozempic" are not alternatives. GLP-1 describes a class of medicines.
The FDA's 2025 prescribing information lists different approved uses for the two products. Both contain semaglutide, but Ozempic is approved mainly for type 2 diabetes, while Wegovy is approved for long-term weight reduction and weight maintenance in eligible adults and adolescents. In the 68-week STEP 1 trial, people who received semaglutide 2.4 mg weekly with lifestyle changes lost an average of 14.9% of their starting body weight.
Ozempic vs. Wegovy for Weight Loss
| Factor | Ozempic | Wegovy |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| Drug class | GLP-1 receptor agonist | GLP-1 receptor agonist |
| Main FDA-approved use | Type 2 diabetes, with certain cardiovascular and kidney-related benefits | Chronic weight management, weight maintenance and, for certain patients, cardiovascular risk reduction |
| Usual injectable maintenance dose | Up to 2 mg once weekly, depending on the indication | Usually 2.4 mg once weekly for weight management |
| Weight-loss evidence | Weight loss is a secondary effect in diabetes trials | Specifically studied and approved for obesity and overweight |
| Best fit | Someone with type 2 diabetes who also wants to lose weight | Someone whose main treatment goal is weight loss |
Weight loss is not an FDA-listed indication for Ozempic. Prescribing Ozempic specifically for weight loss is therefore off-label. Wegovy has an obesity-specific indication.
Why Wegovy Usually Wins for Weight Loss
Wegovy has more direct evidence for treating obesity. In the 68-week STEP 1 trial, adults with overweight or obesity who received semaglutide 2.4 mg weekly alongside lifestyle changes lost an average of 14.9% of their starting body weight, compared with 2.4% with placebo.
The higher semaglutide dose used for weight management also produced more weight loss than the 1 mg dose studied in people with type 2 diabetes. In STEP 2, average weight loss after 68 weeks was 9.6% with semaglutide 2.4 mg and 7.0% with semaglutide 1 mg. This was not a direct comparison between the Ozempic and Wegovy brands, so individual results can differ.
When Ozempic May Be the Better Choice
Ozempic may be more appropriate when you:
- Have type 2 diabetes and need treatment to improve blood glucose control.
- Need one of Ozempic's approved cardiovascular or kidney-related indications.
- Have a prescriber who determines that Ozempic's benefits outweigh its limitations for your situation.
Ozempic can still cause meaningful weight loss, but it was not developed or FDA-approved as the primary weight-management product. Results depend on the dose, treatment duration, medical conditions, diet, activity level and how well you tolerate the medication.
Is a GLP-1 Better Than Ozempic?
The comparison depends on the exact medication and dose. Ozempic is one GLP-1 medication, while other GLP-1 or related medicines include:
- Wegovy: semaglutide approved for chronic weight management.
- Saxenda: liraglutide approved for weight management.
- Zepbound: tirzepatide, a related GIP/GLP-1 medicine approved for chronic weight management.
Before comparing results, identify the exact medication and dose. A 2.4 mg weekly semaglutide regimen for weight management is not the same treatment as a lower-dose semaglutide regimen prescribed for diabetes.
Important Risks and Limitations
Ozempic and Wegovy can cause nausea, vomiting, diarrhea, abdominal pain and constipation. Their prescribing information also warns about pancreatitis, gallbladder disease, dehydration-related kidney injury, severe gastrointestinal reactions and serious allergic reactions.
People with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should not use Ozempic or Wegovy. These medicines should not be combined with another semaglutide product or another GLP-1 receptor agonist unless a qualified prescriber specifically directs it.
Weight can return after stopping semaglutide. Long-term weight management usually requires an ongoing plan that includes nutrition, physical activity and medical follow-up.
Bottom Line
For someone whose main goal is weight loss, Wegovy is generally the better semaglutide choice because it is FDA-approved for chronic weight management and has dedicated weight-loss trial evidence. Ozempic may be the better choice when type 2 diabetes, cardiovascular disease or kidney disease is the primary medical concern.
Do not switch between Ozempic, Wegovy or another GLP-1 medication without speaking with your prescriber.